Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation founded in 1886 by three brothers: Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson. ## Company Overview Key highlights: - Headquarters: New Brunswick, New Jersey - Publicly traded on NYSE - Dow Jones Industrial Average component - Ranked 40th on 2023 Fortune 500 list - Global workforce: Approximately 130,000 employees - Current CEO: Joaquin Duato ## Business Segments J&J operates through three primary business segments: 1. Pharmaceutical 2. Medical Devices 3. Consumer Health (recently spun off as Kenvue in May 2023) ### Pharmaceutical Focus Areas - Immunology - Infectious diseases - Neuroscience - Oncology - Pulmonary hypertension - Cardiovascular and metabolic diseases ## Financial Performance **Q2 2024 Highlights**: - Net earnings: $4.6 billion (12.8% decrease) - Sales: $22.4 billion (4.3% increase) - EPS: $1.90 (5.9% decrease) **Q3 2024 Highlights**: - Reported sales: $22.5 billion (5.2% growth) - Net earnings: $2.694 billion - Operational sales growth: 6.3% ## Notable Products Top-selling pharmaceuticals in 2021: - Stelara: $9,134 million (psoriasis, Crohn's disease) - Darzalex: $6,023 million (multiple myeloma) - Imbruvica: $4,369 million (oncology) - Invega: $4,022 million (schizophrenia) The company continues to innovate, focusing on breakthrough medical solutions and advancing its global healthcare mission.